Crohn's Disease Clinical Trials

Find Crohn's Disease Clinical Trials Near You

Gallium-68-labeled Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPI-46) PET in Crohn's Disease Patients: a Case-control Study Designed to Illuminate the Spectrum of Fibrostenosis in Patients With Small Bowel Crohn's Disease

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

This study is a prospective, case-control study evaluating whether the PET radiotracer 68Ga-FAPI-46 can detect fibrostenosing Crohn's disease in the small bowel. The goal is to determine whether areas of early or developing fibrosis (pre-stricture changes) demonstrate uptake of the tracer, which binds to fibroblast activation protein (FAP). Participants with small bowel Crohn's disease will be assigned to either a case or control group based on CT or MR enterography findings at enrollment. Cases will include participants who have a small bowel stricture or probable stricture, with or without penetrating complications. Controls will include participants with small bowel Crohn's disease without strictures. Controls may have active inflammatory disease, luminal narrowing, or no active inflammation (including postoperative or chronic changes), as long as no stricture is present. Because most radiologic strictures represent more advanced fibrostenosis, the study aims to enroll a larger proportion of controls to better characterize early fibrotic changes. Approximately one-third to one-half of participants will be cases, and the remainder controls. This design will allow comparison of FAPI uptake patterns in patients with and without strictures to understand how FAP expression relates to the development of small bowel fibrosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Known small bowel Crohn's disease

• Research or clinical MR enterography, or clinical CT enterography, within 3 months.

• Male or female with age greater than 18 years old.

• Diagnosis of Crohn's disease by a gastroenterologist

• Willingness to undergo 68Ga-FAPI-46 PET/CT

• Subjects with the capacity to give informed consent and willingness to provide written consent

Locations
United States
Minnesota
Mayo Clinic
RECRUITING
Rochester
Contact Information
Primary
Brian Will
will.brian@mayo.edu
507-266-0111
Backup
Yong S Lee
lee.yong@mayo.edu
507-538-4446
Time Frame
Start Date: 2026-01-26
Estimated Completion Date: 2027-04-30
Participants
Target number of participants: 45
Treatments
Experimental: A group of participants getting PET/CT scan with 68Ga-FAPI-46
Ga68-FAPI-46 radioactive tracer binding to FAP
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic
Collaborators: The Leona M. and Harry B. Helmsley Charitable Trust

This content was sourced from clinicaltrials.gov